Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, blocks mineralocorticoid receptor overactivation.13, , –16 Finerenone, in addition to maximum tolerated renin-angiotensin system inhibition, was evaluated in two complementary phase 3 trials, including participants across the CKD spectrum with concomitant type 2 diabetes. This evidence concerns the gene NR3C2 and type 2 diabetes mellitus.